Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study

皮肤科生活质量指数 医学 银屑病面积及严重程度指数 安慰剂 银屑病 内科学 随机对照试验 生活质量(医疗保健) 不利影响 皮肤病科 病理 替代医学 护理部
作者
Seong Jun Seo,Bong Seok Shin,Joo‐Heung Lee,Haeyoun Jeong
出处
期刊:Journal of Dermatology [Wiley]
卷期号:48 (6): 807-817 被引量:15
标识
DOI:10.1111/1346-8138.15733
摘要

Abstract Psoriasis, a chronic inflammatory skin disease, negatively impacts patients’ quality of life (QoL). This randomized, phase III, double‐blind, placebo‐controlled, multicenter study evaluated the efficacy and safety of brodalumab, a human anti‐interleukin‐17 receptor A monoclonal antibody, in Korean patients with moderate to severe plaque psoriasis. Coprimary end‐points were the percentage of patients with 75% or more improvement in Psoriasis Area and Severity Index (PASI 75) and static Physician’s Global Assessment (sPGA) success (score 0/1) at week 12. Secondary end‐points included the percentage improvement from baseline in PASI score and proportion of patients with PASI 50/75/90/100 responses. QoL was assessed with the Dermatology Life Quality Index (DLQI). Eligible patients were randomized to receive brodalumab 210 mg (N = 40) or placebo (N = 22) every 2 weeks (Q2W) at a 2:1 ratio for 12 weeks. Subsequently, all patients entered an open‐label extension phase and received brodalumab 210 mg Q2W until week 62. At week 12, the proportion of patients who achieved the coprimary end‐points, PASI 75 and sPGA success, was significantly higher in the brodalumab 210 mg Q2W group compared with the placebo group (92.5% vs 0%). At week 12, the mean ± SD percentage improvement in the PASI score was 96.87 ± 6.01% in the brodalumab 210 mg Q2W group, which was maintained until study end (week 64). PASI 50/75/90 responses were achieved by 100% of patients receiving brodalumab 210 mg Q2W at weeks 6, 13, and 24, respectively; PASI 100 was achieved by 82.8% of patients at week 64. Brodalumab treatment rapidly improved DLQI scores. The most common treatment‐emergent adverse events were nasopharyngitis, upper respiratory tract infections, tinea pedis, and urticaria. Overall, treatment with brodalumab 210 mg Q2W resulted in a rapid and significant clinical benefit and was well tolerated in patients with moderate to severe plaque psoriasis in Korea.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
WzJCW完成签到,获得积分20
刚刚
梦寐寤寐发布了新的文献求助10
刚刚
1秒前
王12完成签到,获得积分10
2秒前
2秒前
3秒前
3秒前
4秒前
skip发布了新的文献求助10
4秒前
4秒前
Ican发布了新的文献求助10
4秒前
4秒前
通过发布了新的文献求助10
5秒前
不安的问雁完成签到,获得积分20
5秒前
拜拜拜仁完成签到,获得积分10
5秒前
晨晨的应助被WSND采纳,获得50
7秒前
8秒前
9秒前
10秒前
orange发布了新的文献求助10
10秒前
10秒前
chris chen完成签到,获得积分10
10秒前
10秒前
哈哈哈哈发布了新的文献求助10
10秒前
beibei发布了新的文献求助10
10秒前
10秒前
11秒前
ying777完成签到,获得积分20
12秒前
12秒前
xl发布了新的文献求助10
13秒前
15秒前
充电宝的应助被ZB采纳,获得10
15秒前
16秒前
16秒前
Rina发布了新的文献求助10
16秒前
17秒前
JiaQi完成签到,获得积分10
18秒前
无敌黄金发布了新的文献求助10
19秒前
忆深完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192903
求助须知:如何正确求助?哪些是违规求助? 9579325
关于积分的说明 21864493
捐赠科研通 7792494
什么是DOI,文献DOI怎么找? 3437087
关于科研通互助平台的介绍 2560652
邀请新用户注册赠送积分活动 2483937